{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:05:40Z","timestamp":1790960740151,"version":"4.1.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy against multiple myeloma (MM). However, several barriers continue to limit the overall effectiveness of this approach, such as high production costs, prolonged manufacturing timelines, safety issues, and the potential for tumor antigen escape due to selective therapeutic pressure. To overcome these challenges, innovative CAR T strategies, such as engineering modular CAR systems, are being explored. These systems utilize adaptor molecules to enable multi-antigen targeting, thereby enhancing specificity, safety, and overall efficiency of CAR T-cell therapy. Notably, CAR T-cells directed against BCMA and SLAMF7 antigens have generated strong and robust antitumor responses in MM therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To address the limitations of conventional CAR T therapy, we developed a novel modular CAR platform targeted against BCMA and SLAMF7. This was achieved using a split intein-mediated protein splicing mechanism, which allows specific covalent peptide bonds to form between CAR modules. This strategy maintains an almost seamless CAR structure, preserving its overall integrity and functionality. The design of the intein-spliced CAR system (termed \"CARtein\") was further optimized through advanced protein structure prediction software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Cells expressing the spliced CARtein constructs, engineered to target BCMA, SLAMF7, or both antigens simultaneously, demonstrated robust and highly specific activation in response to their respective antigens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These results suggest that the CARtein platform is a promising, versatile, and highly specific approach for the modular design and engineering of CARs, enabling multi-antigen targeting while maintaining structural and functional integrity. This modular strategy addresses key limitations of conventional CAR T-cell therapy and may improve both the safety and effectiveness of future MM treatments.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1613222","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:37:51Z","timestamp":1753940271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma"],"prefix":"10.3389","volume":"16","author":[{"given":"Noelia","family":"Moares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Gonzalez-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Yi-He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Mu\u00f1oz-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gabucio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Luna-Espejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Oca\u00f1a-Cuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Fernandez-Cisnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia M.","family":"Fernandez-Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Garcia-Cozar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168996","article-title":"CAR T-cell therapy in hematological Malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.925985","article-title":"CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments","volume":"13","author":"Jogalekar","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk-stratification and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41408-020-0337-y","article-title":"B-cell maturation antigen expression across hematologic cancers: a systematic literature review","volume":"10","author":"Dogan","year":"2020","journal-title":"Blood Cancer J"},{"key":"B10","article-title":"CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am J Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.868695","article-title":"The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6721","article-title":"The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30090573","article-title":"SLAMF7 as a promising immunotherapeutic target in multiple myeloma treatments","volume":"30","author":"Chu","year":"2023","journal-title":"Curr Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02399-5","article-title":"Conventional CARs versus modular CARs","volume":"68","author":"Feldmann","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197222","article-title":"Modular chimeric antigen receptor systems for universal CAR T cell retargeting","volume":"21","author":"Sutherland","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.9b11622","article-title":"Quantitative control of gene-engineered T\u2212Cell activity through the covalent attachment of targeting ligands to a universal immune receptor","volume":"142","author":"Minutolo","year":"2020","journal-title":"J Am Chem Soc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920910347","article-title":"Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release","volume":"12","author":"Liu","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2013.10.021","article-title":"Structural analysis and optimization of the covalent association between spyCatcher and a peptide tag","volume":"426","author":"Li","year":"2014","journal-title":"J Mol Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12943-024-01938-8","article-title":"The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments","volume":"23","author":"Chen","year":"2024","journal-title":"Mol Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41467-020-15272-2","article-title":"An expanded library of orthogonal split inteins enables modular multi-peptide assemblies","volume":"11","author":"Pinto","year":"2020","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioteChadv.2024.108349","article-title":"Inteins: A Swiss army knife for synthetic biology","volume":"73","author":"Anastassov","year":"2024","journal-title":"Biotechnol Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.810180","article-title":"Protein splicing of inteins: A powerful tool in synthetic biology","volume":"10","author":"Wang","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.372680","article-title":"Unprecedented rates and efficiencies revealed for new natural split inteins from metagenomic sources","volume":"287","author":"Carvajal-Vallejos","year":"2012","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav4523","article-title":"Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina","volume":"11","author":"Tornabene","year":"2019","journal-title":"Sci Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202200487","article-title":"Harnessing split-inteins as a tool for the selective modification of surface receptors in live cells","volume":"24","author":"Ray","year":"2023","journal-title":"ChemBioChem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv601","article-title":"Development of an intein-mediated split-Cas9 system for gene therapy","volume":"43","author":"Truong","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"8360","DOI":"10.1038\/s41598-017-08641-3","article-title":"Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system","volume":"7","author":"Han","year":"2017","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat Methods"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-024-01011-0","article-title":"The HADDOCK2.4 web server for integrative modeling of biomolecular complexes","volume":"19","author":"Honorato","year":"2024","journal-title":"Nat Protoc"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1021\/sb200015u","article-title":"SYNZIP protein interaction toolbox: in vitro and in vivo specifications of heterospecific coiled-coil interaction domains","volume":"1","author":"Thompson","year":"2012","journal-title":"ACS Synth Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaa009","article-title":"The Protein Imager: a full-featured online molecular viewer interface with server-side HQ-rendering capabilities","volume":"36","author":"Tomasello","year":"2020","journal-title":"Bioinformatics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jim.2016.01.007","article-title":"Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-\u03baB, NFAT and AP-1","volume":"430","author":"Jutz","year":"2016","journal-title":"J Immunol Methods"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087641","article-title":"Specific activation of T cells by an ACE2-based CAR-like receptor upon recognition of SARS-coV-2 spike protein","volume":"24","author":"Gonzalez-Garcia","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3892\/ol.2014.2684","article-title":"Optimization of lentiviral vector production using polyethylenimine-mediated transfection","volume":"9","author":"Tang","year":"2015","journal-title":"Oncol Lett"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2023.12.001","article-title":"The SpyCatcher-SpyTag interaction mediates tunable anti-tumor cytotoxicity of NK cells","volume":"165","author":"Guo","year":"2024","journal-title":"Mol Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.04.080","article-title":"Rational design and production of a chimeric antigen targeting Zika virus that induces neutralizing antibodies in mice","volume":"42","author":"Miranda-L\u00f3pez","year":"2024","journal-title":"Vaccine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061234","article-title":"KDEL receptors: pathophysiological functions, therapeutic options, and biotechnological opportunities","volume":"10","author":"Cela","year":"2022","journal-title":"Biomedicines"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.11.015","article-title":"Chimeric antigen receptor library screening using a novel NF-\u03baB\/NFAT reporter cell platform","volume":"27","author":"Rydzek","year":"2019","journal-title":"Mol Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1038\/s41467-022-31035-7","article-title":"Antigen glycosylation regulates efficacy of CAR T cells targeting CD19","volume":"13","author":"Heard","year":"2022","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fmmed.2023.1070384","article-title":"Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors","volume":"3","author":"Jahan","year":"2023","journal-title":"Front Mol Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo0514","article-title":"CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome","volume":"8","author":"Rodriguez-Marquez","year":"2022","journal-title":"Sci Adv"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/pr9050874","article-title":"Protein L\u2014More than just an affinity ligand","volume":"9","author":"Kittler","year":"2021","journal-title":"Processes"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1118539109","article-title":"Type II membrane protein CD69 regulates the formation of resting T-helper memory","volume":"109","author":"Shinoda","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112964","article-title":"Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: results of the compassionate use or the expanded access program in Spain","volume":"15","author":"de la Rubia","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1021\/acssynbio.7b00208","article-title":"Split2 protein-ligation generates active IL-6-type hyper-cytokines from inactive precursors","volume":"6","author":"Moll","year":"2017","journal-title":"ACS Synth Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101422","article-title":"Novel CS1 CAR-T cells and bispecific CS1-BCMA CAR-T cells effectively target multiple myeloma","volume":"9","author":"Golubovskaya","year":"2021","journal-title":"Biomedicines"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.302","article-title":"A compound chimeric antigen receptor strategy for targeting multiple myeloma","volume":"32","author":"Chen","year":"2018","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000972512.53497.1f","article-title":"P1406: safety and efficacy of ibi346, A first-in-class bcma-targeting modular car-T cell therapy, for patients with relapsed\/refractory multiple myeloma (Rrmm): preliminary results from two phase I studies","volume":"7","author":"Fu C","year":"2023","journal-title":"Hemasphere"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114358","article-title":"Advances in modular control of CAR-T therapy with adapter-mediated CARs","volume":"187","author":"McCue","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg3072","article-title":"Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid Malignancies","volume":"14","author":"Greco","year":"2022","journal-title":"Sci Trans Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204386","article-title":"Rao A. Partners in transcription: NFAT and AP-1","volume":"20","author":"Maci\u00e1n","year":"2001","journal-title":"Oncogene"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.17.4783","article-title":"Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun","volume":"19","author":"Maci\u00e1n","year":"2000","journal-title":"EMBO J"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646837","article-title":"CD69: from activation marker to metabolic gatekeeper","volume":"47","author":"Cibri\u00e1n","year":"2017","journal-title":"Eur J Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1399544","article-title":"Challenges and innovations in CAR-T cell therapy: a comprehensive analysis","volume":"14","author":"Luo","year":"2024","journal-title":"Front Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2013.01.023","article-title":"Function of cd3\u03f5-mediated signals in T cell development","volume":"192","author":"Sommers","year":"2000","journal-title":"J Exp Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005430","article-title":"Comparison of T cell receptor-induced proximal signaling and downstream functions in immortalized and primary T cells","volume":"4","author":"Bartelt","year":"2009","journal-title":"PloS One"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-012542","article-title":"CD28-mediated regulation of multiple myeloma cell proliferation and survival","volume":"109","author":"Bahlis","year":"2007","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nri1248","article-title":"CD28-mediated co-stimulation: a quantitative support for TCR signalling","volume":"3","author":"Acuto","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401845","article-title":"Controlling NF-\u03baB activation in T cells by costimulatory receptors","volume":"13","author":"Schmitz","year":"2006","journal-title":"Cell Death Differ"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signalling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1006\/jmbi.2000.4265","article-title":"Stability engineering of antibody single-chain Fv fragments1","volume":"305","author":"W\u00f6rn","year":"2001","journal-title":"J Mol Biol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0451","article-title":"Modifications to the framework regions eliminate chimeric antigen receptor tonic signaling","volume":"9","author":"Landoni","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"Oncoimmunology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.91","article-title":"Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc \u2018spacer\u2019 domain in the extracellular moiety of chimeric antigen receptors avoids \u2018off-target\u2019 activation and unintended initiation of an innate immune response","volume":"17","author":"Hombach","year":"2010","journal-title":"Gene Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1038\/s41467-023-41631-w","article-title":"Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1039\/C3SC52951G","article-title":"Inteins: nature\u2019s gift to protein chemists","volume":"5","author":"Shah","year":"2014","journal-title":"Chem Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2008.01.007","article-title":"An engineered protein tag for multiprotein labeling in living cells","volume":"15","author":"Gautier","year":"2008","journal-title":"Chem Biol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/s41467-023-37863-5","article-title":"Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting","volume":"14","author":"Ruffo","year":"2023","journal-title":"Nat Commun"},{"key":"B83","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12967-023-04041-6","article-title":"Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility","volume":"21","author":"Celichowski","year":"2023","journal-title":"J Transl Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1115485109","article-title":"Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin","volume":"109","author":"Zakeri","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1305848","article-title":"Inteins\u2014mechanism of protein splicing, emerging regulatory roles, and applications in protein engineering","volume":"14","author":"Wood","year":"2023","journal-title":"Front Microbiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1613222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:37:52Z","timestamp":1753940272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1613222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":85,"alternative-id":["10.3389\/fimmu.2025.1613222"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1613222","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"article-number":"1613222"}}